Literature DB >> 7829397

Characterization of mice bearing subclones of colon 26 adenocarcinoma disqualifies interleukin-6 as the sole inducer of cachexia.

K Soda1, M Kawakami, A Kashii, M Miyata.   

Abstract

A subclone (clone 20) of chemically induced, murine colon adenocarcinoma with a potent ability to induce cachexia and another subclone (clone 5) without such an activity were transplanted to syngeneic mice (CDF1) and their tissue weights, blood components and cytokine levels in sera were compared. Mice transplanted with clone 20 showed a profound body-weight loss by 15 days after inoculation when the tumor accounted for less than 1% of the body weight, along with marked reduction of food and water intakes. Thereafter, they transiently gained in body weight with restoration of food and water intakes. Thus, the change in body weight was biphasic and not proportional to the tumor size. Body fat was lost preferentially, accompanied with a decrease in plasma triglyceride levels. The thymus contracted remarkably, and the peripheral lymphocyte count decreased extensively. Mice transplanted with clone 5, in contrast, did not show any of these changes characteristic of cachexia. Serum concentration of interleukin-6, which has been proposed as the principal inducer of cachexia in mice with colon 26, increased in mice with clone 5 to levels comparable to those in mice with clone 20. The changes in mice bearing clone 20 could not all be explained in terms of known biological activities of interleukin-6. Additional unknown factors, therefore, are presumed to contribute to cachexia in mice with clone 20. Identification of them should be helpful in the care of cachectic patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7829397      PMCID: PMC5919366          DOI: 10.1111/j.1349-7006.1994.tb02917.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  31 in total

Review 1.  Specificity in metabolic effects of cachectin/TNF and other related cytokines.

Authors:  M Kawakami; N Watanabe; H Ogawa; T Murase; N Yamada; H Sando; S Shibata; T Oda; F Takaku
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

Review 2.  A spectrum of tumors that produce paraneoplastic syndromes. Lung tumors: how they produce their syndromes.

Authors:  L Nathanson; T C Hall
Journal:  Ann N Y Acad Sci       Date:  1974       Impact factor: 5.691

3.  Purification of a lipoprotein lipase-inhibiting protein produced by a melanoma cell line associated with cancer cachexia.

Authors:  M Mori; K Yamaguchi; K Abe
Journal:  Biochem Biophys Res Commun       Date:  1989-05-15       Impact factor: 3.575

4.  Production of lipolytic and proteolytic factors by a murine tumor-producing cachexia in the host.

Authors:  S A Beck; M J Tisdale
Journal:  Cancer Res       Date:  1987-11-15       Impact factor: 12.701

5.  Suppression of lipoprotein lipase in 3T3-L1 cells by a mediator produced by SEKI melanoma, a cachexia-inducing human melanoma cell line.

Authors:  M Kawakami; Y Kondo; Y Imai; M Hashiguchi; H Ogawa; A Hiragun; S Aotsuka; S Shibata; T Oda; T Murase
Journal:  J Biochem       Date:  1991-01       Impact factor: 3.387

6.  The roles of gamma-interferon and tumor necrosis factor alpha in an experimental rat model of cancer cachexia.

Authors:  H N Langstein; G M Doherty; D L Fraker; C M Buresh; J A Norton
Journal:  Cancer Res       Date:  1991-05-01       Impact factor: 12.701

7.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

Authors:  W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

8.  Tumors secreting human TNF/cachectin induce cachexia in mice.

Authors:  A Oliff; D Defeo-Jones; M Boyer; D Martinez; D Kiefer; G Vuocolo; A Wolfe; S H Socher
Journal:  Cell       Date:  1987-08-14       Impact factor: 41.582

9.  A new experimental model of human cachexia.

Authors:  A J Strain; G C Easty; A M Neville
Journal:  Invest Cell Pathol       Date:  1979 Apr-Jun

10.  Antitumor activity of indomethacin in mice bearing advanced colon 26 carcinoma compared with those with early transplants.

Authors:  Y Tanaka; T Tanaka; H Ishitsuka
Journal:  Cancer Res       Date:  1989-11-01       Impact factor: 12.701

View more
  13 in total

1.  Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo.

Authors:  Scott Shadfar; Marion E Couch; Kibwei A McKinney; Lisa J Weinstein; Xiaoying Yin; Jessica E Rodríguez; Denis C Guttridge; Monte Willis
Journal:  Nutr Cancer       Date:  2011-06-09       Impact factor: 2.900

2.  A Key Role for Leukemia Inhibitory Factor in C26 Cancer Cachexia.

Authors:  Danielle N Seto; Susan C Kandarian; Robert W Jackman
Journal:  J Biol Chem       Date:  2015-06-19       Impact factor: 5.157

3.  Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse.

Authors:  Paola Aulino; Emanuele Berardi; Veronica M Cardillo; Emanuele Rizzuto; Barbara Perniconi; Carla Ramina; Fabrizio Padula; Enrico P Spugnini; Alfonso Baldi; Fabio Faiola; Sergio Adamo; Dario Coletti
Journal:  BMC Cancer       Date:  2010-07-08       Impact factor: 4.430

4.  Cachexia-associated adipose loss induced by tumor-secreted leukemia inhibitory factor is counterbalanced by decreased leptin.

Authors:  Gurpreet K Arora; Arun Gupta; Sriram Narayanan; Tong Guo; Puneeth Iyengar; Rodney E Infante
Journal:  JCI Insight       Date:  2018-07-26

5.  Splenectomy before tumor inoculation prolongs the survival time of cachectic mice.

Authors:  K Soda; M Kawakami; S Takagi; A Kashii; M Miyata
Journal:  Cancer Immunol Immunother       Date:  1995-10       Impact factor: 6.968

6.  STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia.

Authors:  Andrea Bonetto; Tufan Aydogdu; Noelia Kunzevitzky; Denis C Guttridge; Sawsan Khuri; Leonidas G Koniaris; Teresa A Zimmers
Journal:  PLoS One       Date:  2011-07-20       Impact factor: 3.240

7.  Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients.

Authors:  P Cariuk; M J Lorite; P T Todorov; W N Field; S J Wigmore; M J Tisdale
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  JAK Inhibitors Suppress Cancer Cachexia-Associated Anorexia and Adipose Wasting in Mice.

Authors:  Gurpreet Arora; Arun Gupta; Tong Guo; Aakash Gandhi; Aaron Laine; Dorothy Williams; Chul Ahn; Puneeth Iyengar; Rodney Infante
Journal:  JCSM Rapid Commun       Date:  2020-07-21

9.  Hochuekkito (TJ-41), a Kampo Formula, Ameliorates Cachexia Induced by Colon 26 Adenocarcinoma in Mice.

Authors:  Suzu Yae; Fumiyuki Takahashi; Toshifumi Yae; Takuji Yamaguchi; Rika Tsukada; Kengo Koike; Kunihiko Minakata; Akiko Murakami; Fariz Nurwidya; Motoyasu Kato; Mayumi Tamada; Momoko Yoshikawa; Hiroyuki Kobayashi; Kuniaki Seyama; Kazuhisa Takahashi
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-24       Impact factor: 2.629

10.  Beneficial immune modulatory effects of a specific nutritional combination in a murine model for cancer cachexia.

Authors:  J Faber; P Vos; D Kegler; K van Norren; J M Argilés; A Laviano; J Garssen; A van Helvoort
Journal:  Br J Cancer       Date:  2008-11-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.